Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome ; volume:26 ; number:1 ; day:18 ; month:6 ; year:2024 ; pages:1-12 ; date:12.2024
Arthritis Research & Therapy ; 26, Heft 1 (18.6.2024), 1-12, 12.2024
- Urheber
-
Narváez, Javier
Cañadillas, Elena
Castellví, Iván
Alegre, Juan José
Vicens-Zygmunt, Vanesa
Bermudo, Guadalupe
Vidal-Montal, Paola
Molina Molina, María
Nolla, Joan Miquel
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-024-03353-2
- URN
-
urn:nbn:de:101:1-2409262112037.845326154656
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Narváez, Javier
- Cañadillas, Elena
- Castellví, Iván
- Alegre, Juan José
- Vicens-Zygmunt, Vanesa
- Bermudo, Guadalupe
- Vidal-Montal, Paola
- Molina Molina, María
- Nolla, Joan Miquel
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction: Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome
The natural history of progressive fibrosing interstitial lung diseases
Interstitial lung disease in patients with scleroderma - Treatment with rituximab
The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach
Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review
Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
Correction: Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
Interstitial lung diseases in the hospitalized patient
Interstitial lung disease presents with varying characteristics in patients with non-Hodgkin lymphoma undergoing rituximab-containing therapies
Correction: Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome
The natural history of progressive fibrosing interstitial lung diseases
Interstitial lung disease in patients with scleroderma - Treatment with rituximab
The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach
Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review
Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
Correction: Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
Interstitial lung diseases in the hospitalized patient
Interstitial lung disease presents with varying characteristics in patients with non-Hodgkin lymphoma undergoing rituximab-containing therapies
Correction: Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome
The natural history of progressive fibrosing interstitial lung diseases
Interstitial lung disease in patients with scleroderma - Treatment with rituximab
The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach
Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review
Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
Correction: Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
Interstitial lung diseases in the hospitalized patient